Immunotherapy for Merkel cell carcinoma: A turning point in patient care

Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson

Research output: Contribution to journalArticlepeer-review

Abstract

Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.

Original languageEnglish (US)
Article number23
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - Mar 23 2018
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Immunotherapy for Merkel cell carcinoma: A turning point in patient care'. Together they form a unique fingerprint.

Cite this